Company Overview

Incyte Corporation is a global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of proprietary therapeutics, primarily in oncology and inflammation and autoimmunity. The company’s core competency is small-molecule drug discovery, with a strong emphasis on kinase inhibition and immune modulation. Incyte generates revenue primarily through product sales in the United States and royalties and milestone payments from strategic collaboration partners outside the U.S.

The company’s principal revenue drivers include Jakafi (ruxolitinib) for myeloproliferative neoplasms, Opzelura (ruxolitinib cream) for dermatologic inflammatory conditions, Pemazyre (pemigatinib) for cholangiocarcinoma, and Zynyz (retifanlimab) for certain oncology indications. Founded in 1991, Incyte initially focused on genomics-based drug discovery and later transitioned into a fully integrated biopharmaceutical company with commercial-stage assets, evolving through internal R&D and selective acquisitions.

Business Operations

Incyte operates through integrated research, development, and commercial functions, with its business largely organized around Oncology and Inflammation & Autoimmunity therapeutic areas. The company conducts discovery and early development internally, while also advancing late-stage clinical programs and commercializing approved products, primarily in the United States. Outside the U.S., Incyte relies on strategic partners for commercialization while retaining development and manufacturing oversight.

The company controls proprietary drug discovery platforms, clinical development capabilities, and manufacturing through a combination of internal facilities and third-party manufacturers. Key subsidiaries include Incyte Corporation (U.S.) and Incyte Biosciences International Sàrl, which manages international operations. Major partnerships include long-standing collaborations with Novartis for ex-U.S. commercialization of ruxolitinib (marketed as Jakavi) and with Eli Lilly and Company related to baricitinib, which provides royalty income.

Strategic Position & Investments

Incyte’s strategy centers on expanding the lifecycle of its flagship products, advancing a deep clinical pipeline, and selectively acquiring assets that strengthen its oncology and immunology franchises. Growth initiatives include label expansions for Jakafi and Opzelura, continued development of novel immune-oncology agents, and investment in late-stage clinical programs with near- to mid-term commercialization potential.

A major strategic investment was the acquisition of MorphoSys AG in 2024, which added the oncology product Monjuvi (tafasitamab) and the late-stage asset pelabresib to Incyte’s portfolio. The company continues to invest heavily in emerging areas such as immune checkpoint inhibition, targeted protein degradation, and combination therapies, positioning itself as a mid-sized biopharmaceutical company with both durable cash flows and pipeline-driven growth.

Geographic Footprint

Incyte is headquartered in Wilmington, Delaware, and has a significant operational presence in North America and Europe. U.S. operations account for the majority of product sales, research activities, and corporate functions, while European operations support international clinical development and partnered commercial activities.

The company’s products reach patients globally through a combination of direct sales in the United States and partner-led commercialization across Europe, Asia, and other international markets. Through licensing agreements and royalties, Incyte maintains economic exposure to key global pharmaceutical markets without maintaining a fully integrated commercial infrastructure in every region.

Leadership & Governance

Incyte is led by an executive team with deep experience in biopharmaceutical research, development, and commercialization. The leadership emphasizes disciplined capital allocation, science-driven innovation, and long-term value creation through proprietary assets and strategic partnerships.

Key executives include:

• Hervé Hoppenot – President and Chief Executive Officer
• Steven Stein, M.D. – Chief Medical Officer
• Barry Flannelly – Executive Vice President and Chief Financial Officer
• Paul Hamilton – Executive Vice President, General Counsel and Secretary
• Mark V. Heaney – Executive Vice President, Commercial Operations